In our study, all patients with ZNF384-rearranged ALL presented high levels of MRD at day 32 of induction, suggesting that further studies in this subtype could refine the prognostic impact of FLT3 expression. The gene discussed is ZNF384; the disease is acute lymphoblastic leukemia.